Close Menu

licensing agreement

The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms. 

The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.

The technology is used in Qiagen's newly CE-marked test for cervical cancer and is complementary to human papillomavirus screening tests.

Pages